Evidence map›Paper›PMID 23658597›Full record

ArticleTranslational stroke research2013

Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit.

Masato Naraoka, Akira Munakata, Naoya Matsuda, Norihito Shimamura, Hiroki Ohkuma

Open access · hybridAbstract read
In one paragraph

Article in Translational stroke research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Emerging Treatments for Subarachnoid Hemorrhage.CNS & neurological disorders drug targets · 2024
    Review
  9. MicroRNA and their target mRNAs change expression in whole blood of patients after intracerebral hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Cellular Microparticles in Subarachnoid Hemorrhage.Translational stroke research · 2015
    Article
  15. What is early brain injury?Translational stroke research · 2015
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Masato NaraokaDepartment of Neurosurgery, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8216 Japan.
Akira Munakata
Naoya Matsuda
Norihito Shimamura
Hiroki Ohkuma
Hirosaki University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Rho/Rho-kinase pathway is considered important in the pathogenesis of sustained smooth muscle cell contraction during cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). The aims of this study were to investigate whether combination treatment, with pitavastatin as an inhibitor of RhoA and fasudil as an inhibitor of Rho-kinase, prevents the cerebral vasospasm. SAH was simulated using the double-hemorrhage rabbit model, and pitavastatin, or fasudil, or both (combination treatment) were administrated. The basilar artery (BA) cross-sectional area only in the combination treatment group was statistically larger than in the SAH group (p<0.05). BA Rho-kinase, as measured by ELISA, was statistically reduced only in the combination treatment group compared with the SAH group (p<0.05). In the other two treatment groups, pitavastatin or fasudil treatment group showed larger BA cross-sectional areas and lower value for BA Rho-kinase, but there were no statistically significant differences compared with the SAH group. The expression of endothelial nitric oxide synthase (eNOS), evaluated by immunohistochemistry in the pitavastatin group and the combination group, was higher than in the SAH group. Results indicate that combination treatment could extensively prevent cerebral vasospasm due to the synergic effect of combining pitavastatin and fasudil on the Rho/Rho-kinase pathway and on eNOS.

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsBasilar ArteryDrug CombinationsEnzyme-Linked Immunosorbent AssayFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsImmunohistochemistryNitric Oxide Synthase Type IIIQuinolinesRabbitsrho-Associated KinasesSubarachnoid HemorrhageVasospasm, Intracranial1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineDrug CombinationsfasudilHydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide Synthase Type IIIpitavastatinQuinolinesrho-Associated KinasesCerebral vasospasmeNOSFasudilPitavastatinRho/Rho-kinase pathway

Identifiers

PMID23658597
PMCPMC3644406
OpenAlexW2106497350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.